|
We asked 100 pharma leaders, what area do you think will see increased regulatory attention and enforcement in 2013?
| Foreign APIs |
29% |
GMP inspections |
21% |
| Counterfeit medicines |
29% |
| Social media and digital marketing |
8% |
| Other |
13% |
 |
|
|
|
|
|
|
|
5 February, 2013
|
| In this Issue |
R&D: The Widening Gap Between Success and Failure
A new Office of Health Economics (OHE) study finds that out-of-pocket costs to bring a new medicine to market have increased by 600% over the last 30 years, and success rates from proof of concept to registration have decreased at least twofold since the 1980s ...Read more |
The Force Behind the Sales Force: The Importance of the First Line Manager
Torsten Bernewitz asks why building the first line manager (FLM) team — which, he says, is truly the force behind the sales force — is frequently only an afterthought, relegated to a mere span-of-control question that can be decided quickly ... Read more |
Five Compliance Questions to Ask Yourself
At CBI's 10th Annual Pharmaceutical Compliance Congress, Maame Ewusi-Mensah Frimpong, deputy assistant attorney general at the US Department of Justice, offered five questions for chief compliance officers to ask themselves about their colleagues ... Read more |
Is There a Global Policy Gap on Cancer?
Eli Lilly & Co. decided to give yesterday's World Cancer Day its due with the launch of PACE (Patient Access to Cancer care Excellence). The program seeks to build a pro-innovation coalition across the broad cancer community, including, in addition to patient groups, other NGOs in the public health sector, payers, clinicians, academic researchers, regulators and politicians ... Read more
|
|
|
|
